Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer

Breast Cancer Research

Volumn 14, Issue 4, 2012, Pages

  Kim, Jisun ^a   Han, Wonshik ^a,b   Moon, Hyeong Gon ^a   Ahn, Soo Kyung ^a   Shin, Hee Chul ^c   You, Jee Man ^d   Han, Sae Won ^a   Im, Seock Ah ^a   Kim, Tae You ^a   Koo, Hye Ryoung ^a   Chang, Jung Min ^a   Cho, Nariya ^a   Moon, Woo Kyung ^a   Noh, Dong Young ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

^d Sun General Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST DENSITY; CANCER ADJUVANT THERAPY; CANCER SURGERY; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PREDICTION; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; AGED; BREAST NEOPLASMS; DENSITOMETRY; FOLLOW UP; MAMMOGRAPHY; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DENSITOMETRY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 84863498041     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3221     Document Type: Article

References (15)

1. Mousa NA, Crystal P, Wolfman WL, Bedaiwy MA, Casper RF:Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy.Menopause2008,15:875-884.
2. Jeon JH, Kang JH, Kim Y, Lee HY, Choi KS, Jun JK, Oh DK, Lee CY, Ko K, Park EC:Reproductive and hormonal factors associated with fatty or dense breast patterns among korean women.Cancer Res Treat2011, 43:42-48.
3. Ghosh K, Vachon CM, Pankratz VS, Vierkant RA, Anderson SS, Brandt KR, Visscher DW, Reynolds C, Frost MH, Hartmann LC:Independent association of lobular involution and mammographic breast density with breast cancer risk.J Natl Cancer Inst 2010,102:1716-1723.
4. Boyd NF:Tamoxifen, mammographic density, and breast cancer prevention.J Natl Cancer Inst 2011,103:704-705.
5. Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RM:Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.J Natl Cancer Inst 2011,103:744-752.
6. Ali S, Coombes RC:Endocrine-responsive breast cancer and strategies for combating resistance.Nat Rev Cancer2002,2:101-112.
7. Musgrove EA, Sutherland RL:Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer2009,9:631-643.
8. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, Yaffe MJ:Mammographic density and the risk and detection of breast cancer.N Engl J Med2007,356:227-236.
9. Boyd NF, Melnichouk O, Martin LJ, Hislop G, Chiarelli AM, Yaffe MJ, Minkin S:Mammographic density, response to hormones, and breast cancer risk.J Clin Oncol 2011,29:2985-2992.
10. Atkinson C, Warren R, Bingham SA, Day NE:Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen.Cancer Epidemiol Biomarkers Prev1999,8:863-866.
11. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW:Tamoxifen and breast density in women at increased risk of breast cancer.J Natl Cancer Inst 2004,96:621-628.
12. Freedman M, San Martin J, O'Gorman J, Eckert S, Lippman ME, Lo SC, Walls EL, Zeng J:Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo.J Natl Cancer Inst 2001,93:51-56.
13. Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, Tarpinian KS, Powers PP, Wright LA, Donehower MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Garrett-Mayer E, Skaar TC, Davidson NE, Stearns V:Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res (Phila)2011,4:1993-2001.
14. Cigler T, Richardson H, Yaffe MJ, Fabian CJ, Johnston D, Ingle JN, Nassif E, Brunner RL, Wood ME, Pater JL, Hu H, Qi S, Tu D, Goss PE:A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. Breast Cancer Res Treat2011,126:453-461.
15. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ:The quantitative analysis of mammographic densities.Phys Med Biol1994,39:1629-1638.